Stakeholder Summit

A panel of experts provide an overview of the clinical, economic, and humanistic burden of inflammatory conditions in the US, discuss the role of biologics and biosimilars in disease management and practical considerations for drug selection, define interchangeable biosimilars and discuss the potential value of these agents to patients, payers, and providers in the treatment of inflammatory diseases.